A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)
Soohyun Kim, 1, 2,* Siun Kim, 1, 2,* Howard Lee 1– 4 1Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea; 2Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Te...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2020-07-01
|
| Serija: | Drug Design, Development and Therapy |
| Teme: | |
| Online pristup: | https://www.dovepress.com/a-critical-review-of-the-united-states-regulatory-pathways-for-determi-peer-reviewed-article-DDDT |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|